The U.S. Senate on Sunday rejected a Republican amendment to Democratic drug pricing and climate change legislation that would have required federally qualified health centers to make insulin and injectable epinephrine available to patients at or below 340B price.
But
…
The U.S. Senate on Sunday passed historic legislation to let Medicare negotiate the prices of a small number of costly medicines and require drug manufacturers to pay Medicare rebates when prices paid by Medicare rise faster than inflation.
Language in
…
About 100 safety-net provider advocates marched and chanted yesterday on the grounds of the U.S. Capitol to raise awareness in Congress and beyond about threats to the 340B drug pricing program.
The demonstration, organized by Community Voices for 340B (CV340B),
…
Healthcare providers can suppress attacks on and build support for the 340B program by doing more to show the program helps vulnerable patients, the anesthesiologist who served as President Trump’s surgeon general said yesterday.
“We are fighting to deliver care
…
Groups that represent 340B hospitals yesterday asked a federal district judge in Washington, D.C., to immediately halt a nearly 30% Medicare Part B payment cut in place since 2018 for hospitals’ 340B-purchased drugs.
American Hospital Association, America’s Essential Hospitals, Association
…
Purdue Pharma’s Avrio Health subsidiary is giving 340B covered entities refunds for overcharges on Betasept antiseptic surgical scrub for purchases spanning 16 years—from Q2 2005 through Q2 2021. That period covers more than half of the 340B program’s existence.
During
…
Senate Democrats said yesterday they would know this week whether an updated Senate drug pricing bill meets the criteria for passage via budget reconciliation, which requires just 50 Democratic votes. The bill remains on track for a floor vote before
…
The U.S. Health Resources and Services Administration overnight unveiled a new Contract Pharmacy Services page on the 340B program website that addresses requirements for covered entities but not for pharmaceutical manufacturers.
The webpage links to HRSA’s 2010 contract pharmacy final
…
There’s been a burst of activity in federal appellate lawsuits over the legality of drug manufacturers’ conditions on 340B pricing involving contract pharmacies.
During the past two weeks, AstraZeneca, Lilly, Novo Nordisk, and Sanofi filed briefs restating their belief that
…
Hospital groups and health systems asked a federal appeals court on Monday to send their successful U.S. Supreme Court lawsuit over Medicare Part B reimbursement cuts for 340B drugs back to a district court for more proceedings. “The government does
…*Sign up for news summaries and alerts from 340B Report